Brain tumour immunotherapy
Active immunotherapy for brain tumors enhances the effect of surgical and radiation treatments, providing an additional attack vector against the tumor.
Active immunotherapy for brain tumors
Astrocytoma is one of the most common primary brain tumors, developing from astrocytes, which are neuroglial cells. Its treatment is mainly based on surgical removal and radiotherapy.
However, when continued tumor growth occurs after surgery and radiation, the prognosis remains extremely poor. In this situation, active immunotherapy provides an additional mechanism for acting on tumor cells and amplifies the effect of standard treatment.
The method was applied to nine patients — children aged 2–7 years — in whom signs of continued tumour growth persisted after surgery and radiation, and whose prognosis was extremely poor. All of them received multiple vaccinations.
How the treatment works
Immunotherapy comes after surgery and radiation: it helps the body build its own antitumour response.
Adjunct to primary treatment
Immunotherapy is integrated after surgical removal and radiotherapy — acting as an additional vector against residual tumor cells.
Immunotherapy is integrated after surgical removal and radiotherapy — acting as an additional vector against residual tumor cells.
Multiple vaccinations
Patients undergo repeated vaccination courses that form and maintain the antitumor immune response.
Patients undergo repeated vaccination courses that form and maintain the antitumor immune response.
Immune activation
Vaccine-induced immune reactions target the tumor cells and impede their continued growth.
Vaccine-induced immune reactions target the tumor cells and impede their continued growth.
Long-term monitoring
Efficacy is evaluated dynamically over several years by observing the patient's condition.
Efficacy is evaluated dynamically over several years by observing the patient's condition.
Observation Results
Immunotherapy was given to nine children aged 2–7 who retained signs of continued tumor growth after surgery and radiation, and whose prognosis was considered extremely poor.
patients under observation
children aged 2–7 with signs of continued tumor growth
with a distinct clinical effect
the patients were alive and leading full lives
observation period
the results point to the necessity for expanded clinical trials
Method capabilities
Immunotherapy strengthens the effect of surgery and radiation and adds one more mechanism of action on the tumour.
A clinical effect has been seen in patients with signs of continued tumour growth as well.
The method is not accompanied by the heavy toxic burden common with chemotherapy and radiation, nor does it limit daily activities.
Questions about brain tumour treatment
Which brain tumours is the method used for?
Active immunotherapy is used in astrocytoma and glioma after the neuro-oncological situation and the patient's documents have been assessed.
What results have been obtained?
A clear clinical effect was observed in 7 of 9 patients with follow-up of more than five years. This is a small group, and the figures should be read as the centre's experience rather than as trial data.
Can the method be combined with surgery and radiotherapy?
The method acts on tumour cells in a targeted way and without marked systemic toxicity.
Can I travel for treatment from another region?
Yes. The centre is next to Moscow (Khimki, Skhodnya) and accepts patients from other regions; the first consultation can be done remotely from your documents — MRI with written reports and the histology result are needed.
Where to go next
Other conditions in this area
Cost of the course
Doctors in this area
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.